Skip to main content

Global News

Here's what you need to know about Johnson & Johnson's COVID-19 vaccine

71605516102_vaccine.jpg
71605516102_vaccine.jpg
Advertisement
WHAT YOU NEED TO KNOW
  • Johnson & Johnson announced the launch of its large-scale study (Phase 3 trial) to test a two-dose regimen of its experimental COVID-19 vaccine among thousands of volunteers.
  • The U.S. drugmaker plans to enrol up to 30,000 participants globally for the study.
  • The UK arm of the study is aiming to recruit 6,000 participants of the total 30,000 target.
  • This study runs in parallel with Johnson & Johnson’s single-dose regimen trial launched in September, involving 60,000 participants.
Vials of coronavirus disease (COVID-19) vaccine candidate BNT162b2 are sorted at a Pfizer facility in Puurs, Belgium in an undated still image from video. Pfizer/Handout via REUTERS.

WHAT’S THE DIFFERENCE BETWEEN ONE-DOSE & TWO-DOSE REGIMEN?
  • When a COVID-19 vaccine comes to the market, people will likely need two doses. The second dose will allow the body better recognise proteins created by the COVID-19 virus.
  • The second dose will increase immunity. However, how long that immunity lasts remains to be seen.
  • It’s not uncommon to administer two-dose vaccines. Many other vaccines such as ones to protect against measles or rubella require back-to-back doses to be most effective.
  • Last week, Pfizer and BioNTech said interim results from its COVID-19 vaccine trials showed 90 percent effectiveness. This vaccine requires a two-dose regimen to achieve that high effectiveness. The two shots are administered 21 days apart. 
  • In Johnson & Johnson’s two-dose regimen study, participants will be given a first dose of either a placebo or the experimental shot, currently called Ad26COV2, followed by a second dose or placebo 57 days later.
  • The company said the two-dose trial follows positive interim results from the company's study that showed a single dose of its vaccine candidate induced a robust immune response.
A technician inspects vials of coronavirus disease (COVID-19) vaccine candidate BNT162b2 at a Pfizer manufacturing site in manufacturing site in St. Louis, Missouri, U.S. in an undated photograph. Pfizer/Handout via REUTERS.

HOW IS JOHNSON & JOHNSON’S VACCINE DIFFERENT FROM PFIZER’S?
  • Pfizer-BioNtech vaccine uses a new form of biotechnology known as messenger RNA or mRNa.
  • How does it work? mRNA vaccines train the body’s immune system to recognize a threat like a virus. The body then produces antibodies to protect itself against the virus.
  • Meanwhile, Johnson & Johnson’s candidate vaccine uses a common cold virus known as adenovirus type 26, or Ad26, to deliver coronavirus proteins into cells in the body, prompting the body to mount an immune defense against the virus.
  • The vaccine uses the same technology used for Johnson & Johnson's Ebola, Zika and HIV vaccines.
  • Vaccine researcher at Beth Israel Deaconness Dr. Dan Barouch, who led the research in collaboration with Johnson & Johnson said this:  “This study shows that even just a single immunization with the Ad26 vaccine leads to neutralizing antibody responses and robust protection of monkeys against COVID-19.”
A woman holds a small bottle labeled with a

THE POTENTIAL AND CHALLENGES
A worker passes a line of freezers holding coronavirus disease (COVID-19) vaccine candidate BNT162b2 at a Pfizer facility in Puurs, Belgium in an undated photograph. Pfizer/Handout via REUTERS.

Must Watch Video